Economy News How Soaring Demand For Ozempic And Wegovy Is Altering Denmark’s Economy

Denmark's economy boomed on drug exports — Trump's tariffs threat won't be what slows it down

Denmark's economic growth, which economists say is due to an "exceptional surge" in pharmaceutical exports, is expected to weaken this year — but the looming threat of U.S. tariffs on the pharma ... Read More

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ... Read More

Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic

Novo Nordisk cut its outlook as it sees slowing demand for its GLP-1 weight loss and diabetes treatments. Third-quarter profit and revenue was short of analysts' estimates. U.S.-listed shares of Novo ... Read More

Novo Nordisk cuts 2025 forecast again, cites slower sales of Wegovy and Ozempic

Novo Nordisk A/S (NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of its blockbuster drugs Wegovy and Ozempic. This year's sales will rise only as ... Read More

Weight loss drugs are bringing down the country's obesity rate, a survey shows

The number of people using injectable obesity treatments is increasing rapidly, and it is leading to declines in obesity, according to a new survey by the Gallup National Health and Well-Being Index. Read More